27th Jan 2015 08:27
LONDON (Alliance News) - ANGLE PLC said Tuesday that patient data from the Medical University of Vienna supports the use of its Parsortix system for the detection of ovarian cancer.
The parsortix technology is used to capture, harvest and analyse circulating tumour cells in cancer patients.
The University will now collaborate with ANGLE on a clinical study of the use of Parsortix for this purpose, along with the European Network for Translation Research in Ovarian Cancer and the Tumour Bank Ovarian Cancer Network. ANGLE expects this study to take 18 months to complete.
ANGLE said that the Vienna University has been working with a number of systems, including those of ANGLE's competitors, and had described the results using Parsortix as offering "unprecedented sensitivity and specificity."
The company believes that if the clinical study can confirm this patient data, then Parsortix has "the potential to substantially out-perform the current standard of care in ovarian cancer, particularly in relation to specificity."
Shares in ANGLE are trading up 7.5% at 58.88 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle